Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202507666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2025. Verfasst von Wei Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nanoparticles, Kidney Neoplasms, Drug Delivery Systems. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Project of Natural Science Foundation of Liaoning Province, Science and Technology Planning Project of Liaoning Province.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) remains a significant clinical challenge due to delayed diagnosis and multidrug resistance, necessitating innovative strategies to enhance early detection and therapeutic efficacy. This review evaluates the role of lipid‐based nanoparticles (LNPs), including liposomes, micelles, nanoemulsions, solid lipid nanoparticles, and nanostructured lipid carriers, as advanced drug delivery systems in providing innovative solutions for RCC diagnosis and treatment. These LNPs exhibit unique advantages of great biocompatibility, biodegradability, extended circulation, and tumor‐targeting capabilities, which enable precise drug delivery, controlled release, and circumvention of drug resistance mechanisms. After integrating recent advancements, it is highlighted that formulations such as Liposome@Sunitinib can enhance tumor accumulation, two‐drug‐loaded liposomes can activate immune responses, and RNA therapy in combination with immunomodulators can reverse drug resistance. Current findings underscore the transformative potential of lipid‐based nanotechnology in addressing RCC‐specific challenges, particularly in overcoming biological barriers and refining personalized treatment approaches. In the future, multifunctional nano platforms, precision therapies based on patient genes, advanced materials engineering, combination therapies, and sustainable manufacturing can be developed to promote the application of LNPs in the treatment of RCC and realize personalized nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China.
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110000, China.
- Department of Digestive Endoscopy, The Fourth Affiliated Hospital of China Medical University, Shengyang, 110032, China.
- Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
- School of Life Science and Technology, China Pharmaceutical University, 639 Longmian Road, Nanjing, Jiangsu Province, 211198, China.
- Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
ORCID-Profile: Lufeng Zheng
Förderung
- General Project of Natural Science Foundation of Liaoning Province
- Science and Technology Planning Project of Liaoning Province
Zitieren
APA
Yao, W., Lin, Y., Weng, Y., Wu, Y., Zheng, L., Zheng, D., Xi, Q., & Zhao, J. (2025). Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202507666
Vancouver
Yao W, Lin Y, Weng Y, Wu Y, Zheng L, Zheng D, et al. Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202507666
BibTeX
@article{Yao2025,
author = {Yao, Wei and Lin, Yuhe and Weng, Yang and Wu, Yan and Zheng, Lufeng and Zheng, Donghan and Xi, Qi and Zhao, Jingying},
title = {Lipid‐Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202507666}
}
EUVIMED